A detailed history of China Universal Asset Management Co., Ltd. transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 12,002 shares of FULC stock, worth $53,048. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,002
Previous 7,301 64.39%
Holding current value
$53,048
Previous $45,000 6.67%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$3.18 - $9.74 $14,949 - $45,787
4,701 Added 64.39%
12,002 $42,000
Q2 2024

Jul 19, 2024

SELL
$5.98 - $9.31 $27,597 - $42,965
-4,615 Reduced 38.73%
7,301 $45,000
Q1 2024

Apr 29, 2024

BUY
$6.7 - $12.0 $31,932 - $57,192
4,766 Added 66.66%
11,916 $112,000
Q4 2023

May 21, 2024

SELL
$3.18 - $6.86 $15,155 - $32,694
-4,766 Reduced 40.0%
7,150 $48,000
Q4 2023

Jan 23, 2024

BUY
$3.18 - $6.86 $17,668 - $38,114
5,556 Added 348.56%
7,150 $48,000
Q3 2023

May 21, 2024

BUY
$3.25 - $6.08 $2,548 - $4,766
784 Added 96.79%
1,594 $7,000
Q3 2023

Oct 30, 2023

BUY
$3.25 - $6.08 $2,548 - $4,766
784 Added 96.79%
1,594 $7,000
Q2 2023

May 21, 2024

SELL
$2.26 - $3.8 $58 - $98
-26 Reduced 3.11%
810 $2,000
Q2 2023

Jul 27, 2023

SELL
$2.26 - $3.8 $58 - $98
-26 Reduced 3.11%
810 $3,000
Q1 2023

May 21, 2024

BUY
$2.83 - $13.99 $868 - $4,294
307 Added 58.03%
836 $2,000
Q1 2023

Apr 27, 2023

BUY
$2.83 - $13.99 $868 - $4,294
307 Added 58.03%
836 $2,000
Q4 2022

May 21, 2024

SELL
$5.01 - $8.35 $57,048 - $95,081
-11,387 Reduced 95.56%
529 $3,000
Q4 2022

Jan 31, 2023

BUY
$5.01 - $8.35 $210 - $350
42 Added 8.62%
529 $4,000
Q3 2022

Oct 21, 2022

BUY
$4.92 - $9.1 $2,396 - $4,431
487 New
487 $4,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $230M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.